Scotland's life sciences strategy is a welcome vision that must be matched with delivery, says ABPI

The Life Sciences Strategy for Scotland is published today, setting out a vision for how Scottish life sciences will become a £25 billion sector by 2035.

The Strategy aims to create the most effective environment for developing, testing, manufacturing and commercialising life sciences innovation to benefit health and the economy. 

Richard Torbett, Chief Executive of the ABPI said: “Scotland’s Life Sciences Strategy sets a bold and welcome vision, recognising the nation’s strengths in clinical research, world-class health data, and collaboration across industry, academia and the NHS. While this is a challenging moment for the life sciences sector across the UK, Scotland has a real opportunity to demonstrate leadership and build competitive advantage.

“To succeed, ambition must be matched by focused delivery, implementation and critically, rapid, equitable adoption of innovative medicines and vaccines. This not only ensures the best outcomes for patients, but also attracts investment, as global trials naturally follow health systems that routinely use cutting-edge treatments.

“Clear milestones, accountability and success measures for the Strategy will be essential. We are committed to working with the Scottish Government and partners to put it into action, for the benefit of patients, the healthcare system and the economy.”